newest glp 1 drug GLP-1 Drugs from the Gray Market With FDA approval of Wegovy
Description
Gregory JM, Cherrington AD, Moore DJ
1992;102:A756
Some who traditionally would fear injections are willing to try a weekly pen when they hear about significant weight improvements
In practical terms, that means the typical individual in Mississippi would need to spend roughly one-eighth of their annual income to maintain continuous GLP-1 treatment, a cost so steep it would likely require cutting back on essentials or major lifestyle expenses just to afford it
doi: 10.1186/s12933-021-01366-8
